ALT
Altimmune, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow -13.2% ·
net new positions +8.3%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +6 | 85.94M | $261.24M | +14 | −8 |
| Q1 2026 | 78 | 0 | 58.31M | $179.46M | +8 | −8 |
| Q4 2025 | 77 | +2 | 45.71M | $165.02M | +3 | −1 |
| Q3 2025 | 15 | 0 | 25.85M | $97.47M | +1 | −1 |
| Q2 2025 | 12 | +1 | 18.03M | $69.77M | +1 | — |
| Q1 2025 | 8 | -2 | 8.83M | $44.16M | — | −2 |
| Q4 2024 | 10 | +1 | 7.53M | $54.26M | +1 | — |
| Q3 2024 | 8 | 0 | 3.66M | $22.46M | — | — |
| Q2 2024 | 8 | — | 3.17M | $21.05M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 6.37M | — | $24.66M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passive) | 5.17M | — | $20.00M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 5.17M | — | $20.00M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 5.17M | — | $20.00M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | State Street Global Advisors ✦ (passive) | 2.75M | -18.8% | $10.66M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Geode Capital Management ✦ (passive) | 1.93M | +13.4% | $7.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passive) | 1.93M | +13.4% | $7.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 523.46K | New | $2.03M | 0.0% | New | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 437.29K | -61.9% | $1.69M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 401.84K | — | $1.56M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Fidelity (FMR) ✦ | 401.84K | — | $1.56M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 251.87K | +12.0% | $974,722 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Wellington Management ✦ | 251.87K | +12.0% | $974,722 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Wellington Management ✦ | 251.87K | +12.0% | $974,722 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 23 | Millennium Management ✦ | 78.29K | -93.0% | $302,998 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 51.26K | +1.5% | $198,368 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 25 | T. Rowe Price ✦ | 34.23K | +8.8% | $133,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 26 | Marshall Wace ✦ | 22.10K | -98.1% | $85,527 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $2.03M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 69.15M shares, $212.24M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President and CEO · 15.00K sh @ 2.95 · $44,250
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology